Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ -- Bioheart, Inc. (BHRT.QB) will present an update on 12 years of clinical data on MyoCell for treating heart failure at the 8th Annual Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center - - Course Director, Warren Sherman, M.D.

(Logo: )

Howard J. Leonhardt, Founder and Chief Technology Officer of Bioheart, will present data from clinical trials sponsored by the company since 2001.

In Phase II/III clinical trials stage in the U.S. for muscle stem cells for treating advanced heart failure, Bioheart's MyoCell is believed to be the only cell type able to create new contractile muscle in heart scar tissue. Phase II/III Part I interim results demonstrated 95.7 meters improvement in exercise capacity in Bioheart MyoCell patients over placebo (-4 meters) in a double blind randomized study. This compares to -4 meters for CHF drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells, 52 meters for adipose derived cells and 10 meters allogeneic bone marrow derived cells. 

Leonhardt will also provide a look at new generation improvements brought forward to enhance cell transplantation by Bioheart which include: SDF-1 gene transfection, electrical stimulation – see, repeat injections, and nutrient hydrogel. 

Founded in 1999, Bioheart is one of the original cell therapy companies. Since that time, more than 400 heart failure patients have been enrolled in various myoblast therapy clinical trials worldwide.  84% percent of Bioheart MyoCell treated patients have improved while only 16% have worsened.  In placebo and control groups 69% of patients have worsened.

130 more patients are needed to complete the randomized, double blinded, placebo controlled MARVEL trial. MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.  Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

This press release distribution was issued via PR Syndication.

Media Contact: Kristin Comella
13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500

SOURCE Bioheart, Inc.

Posted In: Press Releases